Literature DB >> 9402267

Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment.

G I Meniru1, I L Craft.   

Abstract

An analysis of 581 in-vitro fertilization treatment cycles was carried out to determine the pattern of utilization of retrieved oocytes. Patients were divided into five groups depending on the number of retrieved oocytes. The mean fertilization rate of 57% was broadly similar amongst the groups but the proportion of retrieved oocytes that produced embryos of a quality suitable for transfer or cryopreservation (the cycle efficiency index) fell significantly with increase in the retrieved oocyte number. However, the pregnancy rate increased with the number of retrieved oocytes (13-38%). It is important to determine the point at which advantages of multifollicular development are outweighed by the potential for complications. Increased utilization of retrieved oocytes will decrease the need for production of a large number of oocytes.

Entities:  

Mesh:

Year:  1997        PMID: 9402267     DOI: 10.1093/humrep/12.10.2129

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

1.  A quantitative and morphological analysis of oocytes collected during 438 IVF cycles.

Authors:  C Wittemer; J Ohl; K Bettahar-Lebugle; S Viville; I Nisand
Journal:  J Assist Reprod Genet       Date:  2000-01       Impact factor: 3.412

2.  Is the presence of a non-cleaved embryo on day 3 associated with poorer quality of the remaining embryos in the cohort?

Authors:  Ronit Machtinger; Charles L Bormann; Elizabeth S Ginsburg; Catherine Racowsky
Journal:  J Assist Reprod Genet       Date:  2015-03-15       Impact factor: 3.412

3.  Limitations in use of ovarian reserve biomarkers to predict the superovulation response in small ovarian reserve heifers.

Authors:  Kaitlin R Karl; Janet L H Ireland; Zaramasina L Clark; Robert J Tempelman; Keith E Latham; James J Ireland
Journal:  Theriogenology       Date:  2022-01-31       Impact factor: 2.740

4.  Optimum oocyte retrieved and transfer strategy in young women with normal ovarian reserve undergoing a long treatment protocol: a retrospective cohort study.

Authors:  Yuan-hui Chen; Xiao-hang Xu; Qian Wang; Shao-di Zhang; Li-le Jiang; Cui-lian Zhang; Zhao-jia Ge
Journal:  J Assist Reprod Genet       Date:  2015-09-17       Impact factor: 3.412

5.  The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI.

Authors:  Awoniyi O Awonuga; Karen Wheeler; Mili Thakur; Roohi Jeelani; Michael P Diamond; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-30       Impact factor: 3.412

6.  The total pregnancy potential per oocyte aspiration after assisted reproduction-in how many cycles are biologically competent oocytes available?

Authors:  J G Lemmen; N M Rodríguez; L D Andreasen; A Loft; S Ziebe
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.357

7.  Efficiency of metaphase II oocytes following minimal/mild ovarian stimulation in vitro fertilization.

Authors:  John J Zhang; Mingxue Yang; Zaher Merhi
Journal:  Fertil Res Pract       Date:  2016-09-01

8.  Does the number of oocytes retrieved influence pregnancy after fresh embryo transfer?

Authors:  Qianfang Cai; Fei Wan; Kai Huang; Hanwang Zhang
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

9.  Reproductive efficiency of human oocytes fertilized in vitro.

Authors:  H W Jones; S Oehninger; S Bocca; L Stadtmauer; J Mayer
Journal:  Facts Views Vis Obgyn       Date:  2010

Review 10.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.